<DOC>
	<DOCNO>NCT01111383</DOCNO>
	<brief_summary>This 48-week extension study CMA-0631-PR-0010 Core Study . Patients positive culture P. aeruginosa visit 4 first 8-week core study period and/or deem appropriate Investigators able include 48-week follow-on period ( Extension Study ) continue treatment Bramitob® ( tobramycin nebuliser solution , 300 mg twice daily 4 mL unit dose vial ) .</brief_summary>
	<brief_title>A Single Arm 48-Week Follow-on Safety Study Core Study Comparing Efficacy Tolerability Tobrineb®/Actitob®/Bramitob® Versus TOBI®</brief_title>
	<detailed_description />
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Cystic Fibrosis</mesh_term>
	<mesh_term>Tobramycin</mesh_term>
	<criteria>Successful completion Core Study At least 6 year age Males female</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2011</verification_date>
	<keyword>cystic fibrosis</keyword>
	<keyword>P. aeruginosa</keyword>
	<keyword>tobramycin</keyword>
</DOC>